From: Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology
Characteristic | Patients with follow-up data (N = 799) | Patients without follow-up data (N = 852) | p-value |
---|---|---|---|
Mean age at presentation (SD) | 55.0 (9.8) | 55.5 (10.1) | 2 sample t-test 0.37 |
Cancer Site | Â | Â | Â |
   Breast | 182 (52.4) | 165 (47.6) |  |
   Lung | 120 (44.8) | 148 (55.2) |  |
   Pancreas | 60 (38.2) | 97 (61.8) | Chi-square |
   Colorectal | 90 (51.7) | 84 (48.3) | 0.03 |
   Prostate | 60 (45.5) | 72 (54.5) |  |
   Others | 287 (50.1) | 286 (49.9) |  |
Gender | Â | Â | Â |
   Males | 266 (42.4) | 362 (57.6) | Chi-square |
   Females | 533 (52.1) | 490 (47.9) | < 0.001 |
Treatment History | Â | Â | Â |
   Newly Diagnosed | 410 (53.3) | 359 (46.7) | Chi-square |
   Previously Treated | 389 (44.1) | 493 (55.9) | < 0.001 |
Stage at Diagnosis | Â | Â | Â |
   Stage 0 | 8 (38.1) | 13 (61.9) |  |
   Stage 1 | 106 (54.6) | 88 (45.4) |  |
   Stage 2 | 164 (49.4) | 168 (50.6) | Chi-square |
   Stage 3 | 208 (52.8) | 186 (47.2) | 0.02 |
   Stage 4 | 244 (43.1) | 322 (56.9) |  |
   Indeterminate | 69 (47.9) | 75 (52.1) |  |